Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSL Of Australia Cleared To Market H1N1 Flu Vaccine By End Of Month

This article was originally published in PharmAsia News

Executive Summary

Australia's CSL has been cleared to market its H1N1 flu vaccine in the country, with the first doses to be available by the end of September

You may also be interested in...



Sandoz Aims For $6bn Biosimilar Business By 2030

Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.

Biogen Bets Big To Bag Sage Depression And Tremor Drugs

Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.

Moderna’s New European Team Readies For COVID-19 Vaccine D-Day

After a stunning first efficacy readout for its mRNA-based vaccine, the biotech company's leaders in Europe talk about their rapid commercial and manufacturing scale-up.

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel